OzagrelThromboxane A2 synthetase inhibitor CAS# 82571-53-7 |
- Rivaroxaban
Catalog No.:BCC2292
CAS No.:366789-02-8
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 82571-53-7 | SDF | Download SDF |
| PubChem ID | 5282440 | Appearance | Powder |
| Formula | C13H12N2O2 | M.Wt | 228.25 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | OKY-046 | ||
| Solubility | DMSO : 50 mg/mL (219.06 mM; Need ultrasonic) | ||
| Chemical Name | (E)-3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enoic acid | ||
| SMILES | C1=CC(=CC=C1CN2C=CN=C2)C=CC(=O)O | ||
| Standard InChIKey | SHZKQBHERIJWAO-AATRIKPKSA-N | ||
| Standard InChI | InChI=1S/C13H12N2O2/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15/h1-8,10H,9H2,(H,16,17)/b6-5+ | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Ozagrel(OKY-046) is an antiplatelet agent working as a thromboxane A2 synthesis inhibitor.
Target: Thromboxane A2 Synthase
Ozagrel was selected as the best compound of highly selective inhibitors of TXA2 synthase. The inhibition of TXA2 synthase by ozagrel was more effective on human and rabbit enzymes than those of other species. Ozagrel increased 6-keto-PGF1 alpha, one of stable metabolites of PGI2, in various isolated cells and tissues perhaps via accumulated PG endoperoxides resulted by the inhibition of TXA2 synthase [1]. Ozagrel was estimated to be a reversible mixed-type inhibitor of diphenolase activity with the constants (K (S1), K (S2), K (i1), and K (i2)) determined to be 2.21, 3.89, 0.454, and 0.799 mM, repectively [2]. Infusion of OKY-046 significantly inhibited pulmonary thromboxane B2 delivery, attenuated the early increase in pulmonary vascular resistance, and blocked the increase in systemic vascular resistance. In addition, OKY-046 blunted and delayed the decrease in cardiac output and maintained end-systolic pressure-diameter relation, +dp/dt, and lung lymph flow at baseline values [3]. References: | |||||
Ozagrel Dilution Calculator
Ozagrel Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.3812 mL | 21.9058 mL | 43.8116 mL | 87.6232 mL | 109.529 mL |
| 5 mM | 0.8762 mL | 4.3812 mL | 8.7623 mL | 17.5246 mL | 21.9058 mL |
| 10 mM | 0.4381 mL | 2.1906 mL | 4.3812 mL | 8.7623 mL | 10.9529 mL |
| 50 mM | 0.0876 mL | 0.4381 mL | 0.8762 mL | 1.7525 mL | 2.1906 mL |
| 100 mM | 0.0438 mL | 0.2191 mL | 0.4381 mL | 0.8762 mL | 1.0953 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Ozagrel is a potent and selective thromboxane A2 synthetase inhibitor with an IC50 of 4 nM.
- Fmoc-Phe(4-I)-OH
Catalog No.:BCC3261
CAS No.:82565-68-2
- Myoscorpine
Catalog No.:BCN1973
CAS No.:82535-76-0
- 5-Methyl-7-methoxyisoflavone
Catalog No.:BCN8465
CAS No.:82517-12-2
- 10-Hydroxy-16-epiaffinine
Catalog No.:BCN4001
CAS No.:82513-70-0
- Deacetylpseudolaric acid A
Catalog No.:BCN4366
CAS No.:82508-37-0
- Demethoxydeacetoxypseudolaric acid B
Catalog No.:BCN4365
CAS No.:82508-36-9
- Methyl pseudolarate B
Catalog No.:BCN4364
CAS No.:82508-34-7
- Methyl pseudolarate A
Catalog No.:BCN4363
CAS No.:82508-33-6
- Pseudolaric acid A
Catalog No.:BCN3717
CAS No.:82508-32-5
- Pseudolaric Acid B
Catalog No.:BCN6284
CAS No.:82508-31-4
- A 784168
Catalog No.:BCC6140
CAS No.:824982-41-4
- LP 44
Catalog No.:BCC7399
CAS No.:824958-12-5
- Moexipril HCl
Catalog No.:BCC5015
CAS No.:82586-52-5
- Quinapril HCl
Catalog No.:BCC5011
CAS No.:82586-55-8
- Sarsaponin
Catalog No.:BCN8293
CAS No.:82597-74-8
- Triacetonamine
Catalog No.:BCN4368
CAS No.:826-36-8
- Mecamylamine hydrochloride
Catalog No.:BCC7501
CAS No.:826-39-1
- Pseudolaric Acid C
Catalog No.:BCN2856
CAS No.:82601-41-0
- Zolpidem
Catalog No.:BCC9194
CAS No.:82626-48-0
- Raloxifene HCl
Catalog No.:BCC4488
CAS No.:82640-04-8
- Picrasidine A
Catalog No.:BCN4369
CAS No.:82652-20-8
- Boc-Tryptophanol
Catalog No.:BCC2700
CAS No.:82689-19-8
- PD 0332991 (Palbociclib) HCl
Catalog No.:BCC3680
CAS No.:827022-32-2
- Palbociclib (PD0332991) Isethionate
Catalog No.:BCC3698
CAS No.:827022-33-3
Effects of vinpocetine and ozagrel on behavioral recovery of rats after global brain ischemia.[Pubmed:24291485]
J Clin Neurosci. 2014 Apr;21(4):661-3.
Brain ischemia leads to severe disruption of the nervous system and recovery is often prolonged. Rehabilitative post-ischemia pharmacological treatment may therefore be important for behavioral recovery, especially for cognition and motor behavior. The present study investigated the effects of combined vinpocetine and Ozagrel administration on the behavioral recovery of rats from global brain ischemia. The results suggest that the combined treatment leads to significantly better improvement compared to single drug administration. We conclude that the combined use of vinpocetine and Ozagrel may provide beneficial effects to patients suffering from brain ischemia.
Preischemic neuroprotective effect of minocycline and sodium ozagrel on transient cerebral ischemic rat model.[Pubmed:25555371]
Brain Res. 2015 Mar 2;1599:85-92.
We investigated the neuroprotective properties of single doses of minocycline and Ozagrel when administered prior to stroke. Male Sprague-Dawley rats were assigned randomly to one of the following groups: (1) control (Con) group (n=10), (2) minocycline (Mino) group (n=10), (3) sodium Ozagrel (SO) group (n=10). Rats were treated with a single dose of minocycline or Ozagrel at 30min before stroke. A middle cerebral artery occlusion (MCAO) was made at 30min after drug administration and reperfusion was done. The rats were subjected to a neurobehavioral test at days 1, 3 and 7 after MCAO. The cerebral ischemic volume was quantified by MetaMorph imaging software after TTC staining. The neuronal cell survival and astrocytes expansion were assessed by the NeuN and GFAP immunohistofluorescence staining. Apoptosis was detected by the TUNEL assay. We statistically analyzed and compared the results with each other. Mino and SO groups had neuroprotective effect and showed a better behavioral performance of adhesive removal and treadmill test at 7 days after stroke. Mino and SO groups also showed a smaller infarct volume than control group at 7 days after stroke. Immunohistofluorescence staining showed a higher number of NeuN positive cells, lower activated astrocytes in GFAP and a lower apoptosis in TUNEL staining. This study showed that single doses of minocycline and Ozagrel prior to stroke had neuroprotective effects. These agents will be useful not only in post-stroke therapy but also in stroke prevention in several cerebrovascular procedures like carotid endarterectomy, bypass procedure, endovascular angioplasty, thromboembolectomy or thrombolysis.
[Pharmacokinetic comparison of two ozagrel polymorph forms in SD rats].[Pubmed:25975032]
Yao Xue Xue Bao. 2015 Feb;50(2):218-21.
To enhance the quality and efficiency of Ozagrel by investigating the differences between the Ozagrel polymorphs in bioavailability. Solid Ozagrel in different polymorph forms were orally administered to SD rats. An HPLC method was established to determinate plasma level of Ozagrel. The bioavailabilities of two polymorph forms were calculated and compared. The pharmacokinetic parameters of Ozagrel, were as follows: Cmax was 32.72 +/- 17.04 and 34.01 +/- 19.13 mg . L(-1), respectively; AUC0-t was 61.14 +/- 14.76 and 85.56 +/- 18.08 mg . L(-1) . h, respectively; t(1/2) was 1.53 +/- 0.51 and 4.73 +/- 3.00 h, respectively. There was no significant difference in pharmacokinetic parameters between form I and II polymorphs of Ozagrel while the t(1/2) of form II is longer, which indicates that the use of form II polymorph as pharmaceutical product may prolong the effective action time in clinics. This would help the polymorph quality control in drug production.
Ozagrel for Patients With Noncardioembolic Ischemic Stroke: A Propensity Score-Matched Analysis.[Pubmed:27567296]
J Stroke Cerebrovasc Dis. 2016 Dec;25(12):2828-2837.
BACKGROUND AND PURPOSE: Ozagrel sodium (Ozagrel), a thromboxane A2 synthesis inhibitor, is used for ischemic stroke patients in several countries, despite a lack of strict evidence of its benefits. We investigated whether Ozagrel was beneficial for patients with atherothrombotic stroke or lacunar infarction. METHODS: This was a retrospective observational study using the Diagnosis Procedure Combination database in Japan. We identified patients with atherothrombotic stroke or lacunar infarction who were admitted to 781 hospitals from July 1, 2010 to March 31, 2012. Propensity score-matched analyses were performed separately for patients with atherothrombotic stroke and those with lacunar infarction, which balanced differences in baseline characteristics between patients who received Ozagrel (Ozagrel group) and those who did not (control group) in each stroke subtype. The modified Rankin Scale scores at discharge and occurrence of hemorrhagic complications after admission were compared between the Ozagrel and control groups. RESULTS: After the propensity score matching, 2726 pairs of patients with atherothrombotic stroke and 1612 pairs of patients with lacunar infarction were analyzed. Ordinal logistic regression analyses showed that Ozagrel use was not significantly associated with modified Rankin Scale score at discharge in patients with atherothrombotic stroke (odds ratio: .99; 95% confidence interval: .88-1.11) or in those with lacunar infarction (odds ratio: 1.00; 95% confidence interval: .87-1.16). The occurrence of hemorrhagic complications did not differ significantly between the Ozagrel and control groups. CONCLUSION: The present study suggested that Ozagrel was safe to use but did not improve functional outcomes in patients with atherothrombotic or lacunar infarction.
